

Current Status of Vilazodone

Mahboobul Hasan Ansari^{1*}, Suhail Ahmed Azmi², Faisal Shaan³

¹Senior Resident, Department of Psychiatry, Faculty of Medicine, Jawaharlal Nehru Medical College, Aligarh, Medical Road, AMU Campus, Aligarh, Uttar Pradesh, India

²Professor and Chairman, Department of Psychiatry, Faculty of Medicine, Jawaharlal Nehru Medical College, Aligarh, Medical Road, AMU Campus, Aligarh, Uttar Pradesh, India

³Junior Resident, Department of Psychiatry, Faculty of Medicine, Jawaharlal Nehru Medical College, Aligarh, Medical Road, AMU Campus, Aligarh, Uttar Pradesh, India

*Corresponding author: Mahboobul Hasan Ansari | Received: 25.12.2018 | Accepted: 06.01.2019 | Published: 17.01.2019

DOI: [10.21276/sjm.2019.4.1.1](https://doi.org/10.21276/sjm.2019.4.1.1)

Abstract

Vilazodone is a serotonin transporter (SERT) and a partial agonist of HT_{1A}. It has been approved by food and drug administration of United States (US FDA) for the treatment of major depressive disorder (MDD) in adults. This agent is considered as a new class of drug “serotonin partial agonist and reuptake inhibitor (SPARI)” by the World Health Organization (WHO). The authors planned to review the drug by using the key word of “vilazodone” on different data base and synthesize a working theory regarding the mechanism of selective serotonin reuptake inhibitor (SSRI) mediated serotonergic neurotransmission. The review also focuses on 5-HT_{1A} autoreceptors. Due to its novel mechanism of action, initially it gave hope to the clinicians and researchers as majority of depressive patients are partial responders or treatment resistant to previously available antidepressants. But later research works suggested that the vilazodone is not much different than the drug available in market. Its side effects were found to be lower than other antidepressant but higher than placebo. It can be concluded that more comparative research between vilazodone and other antidepressant is required in making better opinion about this drug.

Keywords: Vilazodone, 5-HT_{1A}, SPARI, SSRI, MDD.

Copyright © 2019: This is an open-access article distributed under the terms of the Creative Commons Attribution license which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use (NonCommercial, or CC-BY-NC) provided the original author and source are credited.

INTRODUCTION

According to WHO, MDD is a leading cause of disability [1]. It is also the second leading cause of years lived with disability [2]. Introduction of drugs like monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants (TCAs) resulted in landscape change in the management of depression [3]. But the limitation of these drug classes were their adverse effect profiles. Limitations of TCAs are their anticholinergic effects, which also can lead to precipitation of seizures and arrhythmias in overdoses [3, 4] while MAOIs can produce edema and orthostatic hypotension [5, 6].

Shortcomings of previous antidepressants led to the need for a newer, more selective antidepressant having lesser adverse effects. By the decade of 1980, extensive researches lead to the introduction of a more selective class of antidepressants, the SSRIs. These medicines are as efficacious as MAO and TCA with better tolerability.

STAR*D trial has shown that only one third of patients remit with monotherapy in MDD. Four subsequent antidepressant trials demonstrated remission of only two third patients [7]. This indicates that there

was a requirement of a novel antidepressant with a different mechanism of action [8]. US FDA approved Vilazodone (a newer SSRI) on January 2011 which have given hope to fulfill this need by its unique mechanism of action.

METHODOLOGY

We have searched articles related to vilazodone on PubMed and Cochrane data base and internet by using the key word “vilazodone”. The search provided 176 medical literatures out of which 115 were human studies while 44 were related to animal models. Among them 26 were clinical trials, 53 review articles. All the studies thoroughly read by first two authors. We included all research article, review articles, case report which are informative.

Chemical structure

Vilazodone is chemically 2-benzofurancarboxamide, 5-[4- [4 (5 cyano-1H-indol-3-yl) butyl]-1-piperazinyl]-, hydrochloride (1:1). Its molecular weight is 477.99 with chemical formula C₂₆H₂₇N₂O₂ [9, 10].

Mechanism of action

Vilazodone binds to SERT and inhibits it in a dose dependent manner leading to an increase in serotonin levels. Serotonin levels in hippocampus and cortex of rats were found to be increased in “in vivo microdialysis” by this agent [11, 12]. It is also a partial agonist to 5-HT_{1A} receptor, which has additional antidepressant activity [13]. In MDD patients there is an alteration in expression and activity of 5-HT_{1A} receptor in hippocampus raphe nuclei and other cortical regions [14-17]. Serotonergic agent binding to full receptor along with partial receptor (5-HT_{1A}) results in inhibition of serotonin release by neurons [18]. But prolonged 5-HT_{1A} receptor stimulation results in down regulation of the same receptor which is responsible for inhibition of serotonin release [19]. This explains why serotonergic antidepressant takes several weeks for maximum symptomatic improvement [20-22]. Vilazodone desensitizes partial receptor (5-HT_{1A}) more rapidly than conventional SSRI in animal models [23].

Pharmacokinetics

Vilazodone has a half life of approximately 25 hours. Bioavailability of the drug is 72% when it is taken with meal. At steady state, vilazodone 40 mg per day with meal causes mean area under the curve (AUC_{0-24 hr}) around 1,645 ng hours/mL and mean maximum plasma concentration (C_{max}) 156 ng/mL. When vilazodone administered with high fat containing diet, C_{max} raised by 147% to 160% and AUC concentration by 64% to 85%. Vilazodone has a substantially large volume of distribution. It is highly protein bound, approximately 96% to 99% [9, 10]. It is metabolized by cytochrome P450 (CYP) 3A4, CYP2C19 and CYP2D6. In non CYP450 metabolism, carboxyl esterase plays an important role. Only a fraction of drug is excreted in feces (2%) and urine (1%) as an unchanged form. Clearance of drug is not affected in mild to moderate impairment of kidney and liver [9, 10].

Drug interaction

Precaution should be taken if vilazodone is prescribed concomitantly with other serotonergic drugs, like MAO inhibitors, serotonin norepinephrine reuptake inhibitors (SNRIs), SSRIs, buspirone, triptans, tramadol, and tryptophan containing products. If vilazodone is administered within 2 weeks of discontinuation of MAOIs, it may cause serotonin syndrome [9]. Patients who are on strong CYP3A4 inhibitors, like ketoconazole, vilazodone should not be prescribed above 20 mg/day. These inhibitors can raise vilazodone plasma concentration by 50%. There is no dose modification is required in co-administration with cimetidine, another CYP3A4, inhibitor [9].

No data is available on vilazodone plasma levels in subjects concomitantly taking CYP3A4 inducers. But these inducers have the potential to decrease the level of vilazodone. Therefore, patients

who are on warfarin should be monitored closely if they have started vilazodone [9].

Contraindication and precaution

Patients who are prescribed vilazodone should be monitored for abnormal behavior worsening of the symptoms and suicidal ideation. The appearance of signs symptoms suggestive of serotonin syndrome (SS) or neuroleptic malignant syndrome (NMS) warrant discontinuation of vilazodone immediately and begin supportive treatment. One should be very cautious in patients with seizure disorder who are taking vilazodone. Co-administration with NSAID like aspirin can increase bleeding time. To avoid withdrawal symptoms it should be tapered slowly. Depressive patients may switch to mania or hypomania with vilazodone therapy. Therefore, every patient should be screened for bipolarity [9].

Dosage and administration

Vilazodone is available in three strengths 10, 20 and 40 mg. To avoid gastrointestinal side effect it should be started with 10 mg/day for a week, escalate 20 mg/day for next week before achieving 40 mg/day [9].

Adverse effect

Initially, 40 mg or lower dose of vilazodone was supposed neutral on libido. But it is reported that even 20 mg/day can affect sexual desire. So it is too early to say it safe in this regard. Till now there is no head to head trial has been conducted to compare reduction in libido.

Research finding demonstrated that about one in 14 patients taking vilazodone for eight weeks discontinued medication because of unwanted side effects, which is about twice as common as in patients taking placebo [24-26]. The most commonly reported adverse effect demonstrated in clinical trials of patients treated with vilazodone versus placebo were diarrhea (28.0% vs 9.2%), nausea (23.4% vs 5.1%), dizziness (8.5% vs 4.6%), abnormal dreams (4.1% vs 1.2%) and insomnia (6.0% vs 2.1%), vomiting (4.6% vs 1.2%).^{24,27} Dose titration is recommended to minimize gastrointestinal and other adverse effects.

Sexual functioning questionnaire [25] and arizona sexual experiences questionnaire [26] were applied on patients to evaluate sexual function in two different studies. Patients who had taken 8 week treatment of vilazodone, showed minimal sexual dysfunction, similar to placebo [28].

Researchers hypothesized that drug induced sexual dysfunction is minimum due to its partial agonistic activity on 5-HT_{1A} receptors. This hypothesis is supported by studies in which less SSRI induced sexual dysfunction was found, who were also taking 5-HT_{1A} receptor partial agonists (for example, buspirone

or pindolol) [29-32]. More clinical trials are needed which include head to head comparison to test this hypothesis [33].

Trials

Unpublished phase ii studies:

Five, phase II, randomized, double blind, placebo controlled (RCT) study conducted for 8 weeks, compared the efficacy of vilazodone dose ranging from 5–100 mg/day in patients of MDD fulfilling the Diagnostic criteria according to Diagnostic and Statistical Manual-IV (DSM- IV) [31,34].

Three of those five RCTs included placebo as well as an active comparator (two used fluoxetine, 20 mg, and one citalopram, 20 mg) where as rest two did not have an active comparator. Two trials used fixed dose design, whereas the other three used flexible titration design. The primary endpoint measure in all five trials was the mean score change on the 17-item Hamilton Depression Rating Scale (HDRS -17) from baseline to the end point. None of the trials demonstrated superior outcome over placebo at its primary endpoint. Since none of the active comparators demonstrated superior efficacy over placebo, so these trials could be considered as “failed” studies. While the two studies containing only placebo are recognised as “negative” studies. However, the two fixed dose trials showed a possible treatment effect of vilazodone (20 mg/day) over placebo on its secondary outcome measure i.e. Montgomery Asberg Depression Rating Scale (MADRS). It was also observed, depression symptoms decreased vilazodone increased to 20 mg in two phase 2 trials but the observation was not found to be statistically significant.

Published studies

The clinical efficacy of vilazodone over placebo was observed in two 8 weeks, phase III, double-blind, randomized, placebo controlled trials [25, 26] in patients diagnosed with MDD according to DSM-IV-TR criteria [32]. After 8 weeks, there was a significant reduction in scores of MADRS [33] and Hamilton Depression Rating Scale (HDRS-17) [35].

In a trial, at the end of one week, a significant reduction was observed in the scores of MADRS and HDRS-17 in patients who were prescribed vilazodone compared to placebo. This finding suggested that vilazodone has a rapid onset of action [26]. In another trial^{at the end} of six weeks, a significant reduction was observed in scores of MADRS, in patients who were taking vilazodone compared with placebo [25].

Efficacy of vilazodone was assessed by pooling the data from both phase III trials [36]. All the patients (891) were randomized, among them, 431 were prescribed vilazodone and rest were given a placebo. At the end of 8 weeks, there was significantly greater improvement in terms of MADRS score in vilazodone

group patients compared to the placebo group (level of significance was $p < 0.0001$). The significant difference was also seen at the end of the first week and subsequent weeks ($p < 0.01$, all weeks). Similar results were also seen for HDRS-17, Clinical Global Impression Severity of Illness (CGI-S), and Clinical Global Impression-Improvement (CGI-I) scores [37].

Another pooled data analysis confirmed the superiority of vilazodone over placebo in terms of sustained response rate. The cumulative response rate of vilazodone was significantly greater than placebo after 1 week ($p < 0.05$). The time to cumulative response of vilazodone was also significantly faster compared to placebo ($p < 0.0001$). Both the observation indicates that treatment with vilazodone is associated with early and persistent symptomatic improvement and response rate [38].

To evaluate the efficacy of vilazodone in MDD patients, an open label, multicentric trial was conducted in the USA at 39 centres for 1 year. The trial included 599 patients with HDRS-17 more than 18. Only 254 (41.2%) completed the study. Vilazodone was prescribed 40 mg/day over two weeks. Its effectiveness was measured by using MADRS. At baseline, mean MADRS score was 29.9. After 8 weeks the MADRS score reduced to 11.4 and at 52 week score was found 7.1 [39].

Effect of vilazodone on 24 patients diagnosed as adult onset separation anxiety disorder (ASAD) was seen in a 12 week pilot study. The result was evaluated by an independent researcher. Results demonstrated that vilazodone may have role in treatment of ASAD [40].

An open label randomized controlled study on 60 depressive patients conducted in india, which compared vilazodone and escitalopram. The finding of the study was demonstrated that both the drug have equally efficacious. However there is little weight gain and sexual dysfunction in patients taking vilazodone which was statistically significant [41].

Results of a phase three double blind randomized placebo controlled study demonstrated that there is no statistically significant difference among vilazodone 15 mg/day, 30mg/day and placebo in terms of children’s depression rating scale revised version (CDRS-R) and CGI score. There was no significant difference in term of suicidal ideation and suicidal behavior. The most common treatment emergent adverse effect was nausea, vomiting and upper abdominal pain [42].

A meta-analysis compared 16 US FDA approved antidepressant in terms of effect size. Results demonstrated venlafaxine had highest effect size followed by paroxetine. However bupropion and vilazodone had lowest effect size [43].

Black box

Vilazodone has a black box warning regarding suicidality. According to some short term studies, antidepressants have a tendency to increase suicidal thoughts and behaviour in children and young adults when compared to placebo. Hence vilazodone is not approved in children [9].

Limitations of use

One major limitation of vilazodone is its high price comparison to other SSRIs. The cost of one month vilazodone 40 mg/day is around 1000 Indian Rupees. This amount is sufficient for the supply of amitriptyline 50 mg per day for 200 days and escitalopram 10 mg per day for 120 days. Other limitations of its use are inadequate studies, scarcity of data on long term follow up. There is lack of long term studies which compare vilazodone to other antidepressants in terms of adverse effects.

Limitations of review

Not all published trials were included in this review.

CONCLUSION

Vilazodone, a FDA approved antidepressant, was particularly intended to work by inhibiting SERT like an SSRI and as a partial agonist at 5HT_{1A} receptors, very similar to pindolol and buspirone. Its dual mechanism of action results in quicker onset of antidepressant activity, negligible sexual side effects, and enhanced anxiolytic properties. The efficacy of vilazodone in major depressive disorder has been demonstrated in 2 large, randomized, double blind, placebo controlled trials where it has failed to produce its efficacy. In both trials patients showed significant improvement after 8 weeks. In another study, significant improvement was observed as early as a week, although this rapid time course of efficacy remains to be validated. If clinical studies support the theoretical advantages accredited to its dual mechanism of action, vilazodone has the potential of becoming a novel treatment option in the treatment of MDD. Larger and long term clinical trials are needed to assess the efficacy and safety of vilazodone therapy, because patients with acute episodes of MDD may require several months or longer of sustained pharmacological treatment.

Conflict of interest: Nil**REFERENCES**

- Hirschfeld, R. M. (2012). The epidemiology of depression and the evolution of treatment. *The Journal of clinical psychiatry*, 73, 5-9.
- Vos, T., Flaxman, A. D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., ... & Abraham, J. (2012). Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. *The lancet*, 380(9859), 2163-2196.
- Hirschfeld, R. M., Keller, M. B., Panico, S., Arons, B. S., Barlow, D., Davidoff, F., ... & Guthrie, D. (1997). The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. *Jama*, 277(4), 333-340.
- Ferguson, J. M. (2001). SSRI antidepressant medications: adverse effects and tolerability. *Primary care companion to the Journal of clinical psychiatry*, 3(1), 22.
- Remick, R. A., Froese, C., & Keller, F. D. (1989). Common side effects associated with monoamine oxidase inhibitors. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, 13(3-4), 497-504.
- Wimbiscus, M., Kostenko, O., & Malone, D. (2010). MAO inhibitors: Risks, benefits, and lore. *Cleveland Clinic journal of medicine*, 77(12), 859-882.
- Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., ... & McGrath, P. J. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR* D report. *American Journal of Psychiatry*, 163(11), 1905-1917.
- Kocsis, J. H., Leon, A. C., Markowitz, J. C., Manber, R., Arnow, B., Klein, D. N., & Thase, M. E. (2009). Patient preference as a moderator of outcome for chronic forms of major depressive disorder treated with nefazodone, cognitive behavioral analysis system of psychotherapy, or their combination. *The journal of clinical psychiatry*.
- Cruz, M. P. (2012). Vilazodone HCl (Viibryd): a serotonin partial agonist and reuptake inhibitor for the treatment of major depressive disorder. *Pharmacy and Therapeutics*, 37(1), 28.
- Cruz, M. P. (2012). Vilazodone HCl (Viibryd): a serotonin partial agonist and reuptake inhibitor for the treatment of major depressive disorder. *Pharmacy and Therapeutics*, 37(1), 28.
- Page, M. E., Cryan, J. F., Sullivan, A., Dalvi, A., Saucy, B., Manning, D. R., & Lucki, I. (2002). Behavioral and neurochemical effects of 5-[4-[4-(5-cyano-3-indolyl)-butyl]-butyl]-1-piperazinyl]-benzofuran-2-carboxamide (EMD 68843): a combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine_{1A} receptor partial agonist. *Journal of Pharmacology and Experimental Therapeutics*, 302(3), 1220-1227.
- Hughes, Z. A., Starr, K. R., Langmead, C. J., Hill, M., Bartoszyk, G. D., Hagan, J. J., ... & Dawson, L. A. (2005). Neurochemical evaluation of the novel 5-HT_{1A} receptor partial agonist/serotonin reuptake inhibitor, vilazodone. *European journal of pharmacology*, 510(1-2), 49-57.

13. Carr, G. V., & Lucki, I. (2011). The role of serotonin receptor subtypes in treating depression: a review of animal studies. *Psychopharmacology*, 213(2-3), 265-287.
14. Savitz, J., Lucki, I., & Drevets, W. C. (2009). 5-HT1A receptor function in major depressive disorder. *Progress in neurobiology*, 88(1), 17-31.
15. Drevets, W. C., Thase, M. E., Moses-Kolko, E. L., Price, J., Frank, E., Kupfer, D. J., & Mathis, C. (2007). Serotonin-1A receptor imaging in recurrent depression: replication and literature review. *Nuclear medicine and biology*, 34(7), 865-877.
16. Sargent, P. A., Kjaer, K. H., Bench, C. J., Rabiner, E. A., Messa, C., Meyer, J., ... & Cowen, P. J. (2000). Brain serotonin1A receptor binding measured by positron emission tomography with [11C] WAY-100635: effects of depression and antidepressant treatment. *Archives of general psychiatry*, 57(2), 174-180.
17. Stahl, S. (1994). 5HT1A receptors and pharmacotherapy. Is serotonin receptor down-regulation linked to the mechanism of action of antidepressant drugs?. *Psychopharmacology bulletin*, 30(1), 39-43.
18. Blier, P., & Ward, N. M. (2003). Is there a role for 5-HT1A agonists in the treatment of depression?. *Biological psychiatry*, 53(3), 193-203.
19. Stahl, S. M. (1998). Mechanism of action of serotonin selective reuptake inhibitors: serotonin receptors and pathways mediate therapeutic effects and side effects. *Journal of affective disorders*, 51(3), 215-235.
20. Blier, P., & de Montigny, C. (1998). Possible serotonergic mechanisms underlying the antidepressant and anti-obsessive-compulsive disorder responses. *Biological psychiatry*, 44(5), 313-323.
21. Celada, P., Puig, M. V., Amargós-Bosch, M., Adell, A., & Artigas, F. (2004). The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. *Journal of Psychiatry and Neuroscience*, 29(4), 252.
22. Blier, P. (2001). Pharmacology of rapid-onset antidepressant treatment strategies. *The Journal of clinical psychiatry*, 62, 12-17.
23. Ashby Jr, C. R., Kehne, J. H., Bartoszyk, G. D., Renda, M. J., Athanasiou, M., Pierz, K. A., & Seyfried, C. A. (2013). Electrophysiological evidence for rapid 5-HT1A autoreceptor inhibition by vilazodone, a 5-HT1A receptor partial agonist and 5-HT reuptake inhibitor. *European journal of pharmacology*, 714(1-3), 359-365.
24. Citrome, L. (2012). Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant—what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?. *International journal of clinical practice*, 66(4), 356-368.
25. Khan, A., Sambunaris, A., Edwards, J., Ruth, A., & Robinson, D. S. (2014). Vilazodone in the treatment of major depressive disorder: efficacy across symptoms and severity of depression. *International clinical psychopharmacology*, 29(2), 86.
26. Rickels, K., Athanasiou, M., Robinson, D. S., Gibertini, M., Whalen, H., & Reed, C. R. (2009). Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial. *The Journal of clinical psychiatry*, 70(3), 326-333.
27. Frampton, J. E. (2011). Vilazodone. *CNS drugs*, 25(7), 615-627.
28. Clayton, A. H., Kennedy, S. H., Edwards, J. B., Gallipoli, S., & Reed, C. R. (2013). The effect of vilazodone on sexual function during the treatment of major depressive disorder. *The journal of sexual medicine*, 10(10), 2465-2476.
29. Michelson, D., Bancroft, J., Targum, S., Kim, Y., & Tepner, R. (2000). Female sexual dysfunction associated with antidepressant administration: a randomized, placebo-controlled study of pharmacologic intervention. *American Journal of Psychiatry*, 157(2), 239-243.
30. Othmer, E., & Othmer, S. C. (1987). Effect of buspirone on sexual dysfunction in patients with generalized anxiety disorder. *The Journal of clinical psychiatry*.
31. Laughren, T. P., Gobburu, J., Temple, R. J., Unger, E. F., Bhattaram, A., Dinh, P. V., ... & Levin, R. L. (2011). Vilazodone: clinical basis for the US Food and Drug Administration's approval of a new antidepressant. *The Journal of clinical psychiatry*, 72(9), 1166-1173.
32. Castillo, R. J., Carlat, D. J., Millon, T., Millon, C. M., Meagher, S., Grossman, S., ... & American Psychiatric Association. (2007). *Diagnostic and statistical manual of mental disorders*. Washington, DC: American Psychiatric Association Press.
33. Montgomery, S. A., & Åsberg, M. A. R. I. E. (1979). A new depression scale designed to be sensitive to change. *The British journal of psychiatry*, 134(4), 382-389.
34. US Food and Drug Administration. Vilazodone Drug Approval Pack-age.
35. Hamilton, M. (1960). A rating scale for depression. *Journal of neurology, neurosurgery, and psychiatry*, 23(1), 56.
36. Khan, A., Sambunaris, A., Edwards, J., Ruth, A., & Robinson, D. S. (2014). Vilazodone in the treatment of major depressive disorder: efficacy across symptoms and severity of depression. *International clinical psychopharmacology*, 29(2), 86.
37. Malhi, G. S., Hitching, R., Coulston, C. M., Boyce, P., Porter, R., & Fritz, K. (2013). Individualized

- management of unipolar depression. *Acta Psychiatrica Scandinavica*, 127, 1-5.
38. Jain, R., Chen, D., Edwards, J., & Mathews, M. (2014). Early and sustained improvement with vilazodone in adult patients with major depressive disorder: post hoc analyses of two phase III trials. *Current medical research and opinion*, 30(2), 263-270.
 39. Robinson, D. S., Kajdasz, D. K., Gallipoli, S., Whalen, H., Wamil, A., & Reed, C. R. (2011). A 1-year, open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorder. *Journal of clinical psychopharmacology*, 31(5), 643-646.
 40. Schneier, F. R., Moskow, D. M., Choo, T. H., Galfalvy, H., Campeas, R., & Sanchez-Lacay, A. (2017). A randomized controlled pilot trial of vilazodone for adult separation anxiety disorder. *Depression and anxiety*, 34(12), 1085-1095.
 41. Bathla, M., Anjum, S., Singh, M., Panchal, S., & Singh, G. P. (2018). A 12-week comparative prospective open-label randomized controlled study in depression patients treated with vilazodone and escitalopram in a tertiary care hospital in North India. *Indian journal of psychological medicine*, 40(1), 80.
 42. Durgam, S., Chen, C., Migliore, R., Prakash, C., Edwards, J., & Findling, R. L. (2018). A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Vilazodone in Adolescents with Major Depressive Disorder. *Pediatric Drugs*, 1-11.
 43. Monden, R., Roest, A. M., van Ravenzwaaij, D., Wagenmakers, E. J., Morey, R., Wardenaar, K. J., & de Jonge, P. (2018). The comparative evidence basis for the efficacy of second-generation antidepressants in the treatment of depression in the US: A Bayesian meta-analysis of Food and Drug Administration reviews. *Journal of affective disorders*, 235, 393-398.